Pylarify base plus two option years
Ended Awarded Last action
- Contract number
- 36C26225F0053
- Awardee
-
Progenics Pharmaceuticals Inc. UEI YLYKVRPCTCR3 Part of Lantheus Holdings, Inc.
- Awarding agency
-
Veterans Integrated Service Network 22
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- -$16,812
Award facts
- Contract value 0% obligated
-
- $1,554,937.52 Current, with exercised options
- $4,638,437.92 Potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- North Billerica, Billerica, MA 01862, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$16,812 | |
| Original award | $1,571,750 |
About this award
Progenics Pharmaceuticals Inc., operating as a division of Lantheus Medical Imaging, Inc., was awarded a delivery order valued at $4.64 million by Veterans Integrated Service Network 22 on November 1, 2024, for the supply of PYLARIFY (piflufolastat F-18) radiopharmaceutical products. PYLARIFY is a positron emission tomography imaging agent used for the detection and localization of prostate cancer in diagnostic procedures. This firm fixed-price delivery order, which carries no set-aside designation, is scheduled for completion by October 31, 2027, with performance occurring at the company's manufacturing and distribution facility in North Billerica, Massachusetts. The award falls under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) master contract vehicle, which establishes the framework for the Department of Veterans Affairs' procurement of radiopharmaceutical products across the VA system.
This delivery order represents one of numerous individual awards issued to Progenics Pharmaceuticals under broader indefinite delivery vehicle agreements established with VISN 22 and other Veterans Integrated Service Networks. The company maintains an extensive federal contracting presence as a critical supplier of diagnostic imaging agents and radiopharmaceuticals to the VA and Defense Health Agency, with over 150 contract awards from multiple federal healthcare agencies. The firm fixed-price structure provides cost certainty for the VA while enabling efficient procurement of essential oncology diagnostic imaging supplies to support veteran healthcare delivery across the network's medical centers.
Quick answers
Who was awarded contract 36C26225F0053?
36C26225F0053 was awarded to Progenics Pharmaceuticals Inc. by Veterans Integrated Service Network 22 (Veterans Health Administration) on November 1, 2024.
How much is contract 36C26225F0053 worth?
The government has obligated -$16,812 on 36C26225F0053. Its current value, with exercised options, is $1,554,938. Its potential value, with all options, is $4,638,438.
Is contract 36C26225F0053 an order under another contract?
Yes. 36C26225F0053 is a delivery order under 36F79719D0170, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C26225F0053 competed?
The extent of competition for 36C26225F0053 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award